 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 1234» |
- golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
"GOLSEEK-4: A Multicenter Phase 3 Randomized Open-Label Study Comparing Efficacy and Safety of Golcadomide + Rituximab vs Investigator's Choice in Patients with Relapsed/Refractory Follicular Lymphoma" (Congress Hall 1-2 (CC Ost)) - Nov 5, 2025 - Abstract #DGHO2025DGHO_652;
Pts will be followed up to 5 years from LPFV. Enrollment is planned to begin July 2025.Conclusion GOLSEEK-4 will evaluate efficacy and safety of GOLCA+R as fixed duration, chemo-free, outpatient treatment for R/R FL patients who have received ?1 line of systemic therapy.
- lenalidomide / Generic mfg., golcadomide (CC-99282) / BMS
Golcadomide demonstrates potent antiproliferative activity in T-cell lymphoma via degradation of IKZF1 and IKZF3 (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_7889;
Overexpression of thesemutants effectively protected the cells from golcadomide-induced antiproliferation in all tested modelsand also conferred resistance against lenalidomide in lenalidomide-sensitive cell lines.In summary, these findings support the continued development of golcadomide as a promisingtherapeutic for T-cell lymphomas. Its potent efficacy across multiple TCL subtypes and mechanismsinvolving IKZF1 and IKZF3 degradation highlight a novel strategy to address unmet clinical need in thischallenging disease.
- avadomide (CC-122) / BMS, thalidomide / Generic mfg., golcadomide (CC-99282) / BMS
IQGAP1 is a novel non-degraded substrate of CELMoDs and involved in trafficking of immune cells to the tumor microenvironment (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_7369;
This modification increased IQGAP1'sinteraction with Rac, CDC42 and actin, thereby promoting directional immune cell migration. Ourfindings provide the first description of IQGAP1 as a non-degraded CELMoD substrate, directly linking itsbiological function to clinical observation of increased immune cell infiltration into TME.
- lenalidomide / Generic mfg., golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD (OCCC - Tangerine Ballroom F2) - Nov 4, 2025 - Abstract #ASH2025ASH_6313;
P1/2, P3
Ourfindings provide the first description of IQGAP1 as a non-degraded CELMoD substrate, directly linking itsbiological function to clinical observation of increased immune cell infiltration into TME. Median number of prior treatments was 4.5 (range, 2
- Challenges in comparing outcomes of frontline clinical trials for diffuse large B-cell lymphoma patients selected based on the international prognostic index: A real-world analysis from the danish lymphoma registry (OCCC - Tangerine Ballroom F3-4) - Nov 4, 2025 - Abstract #ASH2025ASH_6165;
P3
Variations in IPIthresholds and clinical/laboratory requirements resulted in substantial differences in the proportion oftrial-eligible patients. Among the analyzed trials, ZUMA-23 had the most stringent eligibility criteria,resulting in the lowest eligibility rate and the exclusion of many younger individuals.
- Golseek-1: A Phase 3, double-blind, randomized study of golcadomide (GOLCA), a potential, first-in-class, oral CELMoD (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_5298;
P3
Among the analyzed trials, ZUMA-23 had the most stringent eligibility criteria,resulting in the lowest eligibility rate and the exclusion of many younger individuals. Rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisone (R-CHOP) is the standard first-line treatment for DLBCL, achieving cure rates inapproximately 60
- roginolisib (IOA-244) / iOnctura, golcadomide (CC-99282) / BMS, Onureg (azacitidine oral) / BMS
Plat?form: A multicenter, multi-arm, academic platform trial evaluating novel agents and combinations in relapsed or refractory peripheral T-cell lymphomas (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_4666;
P1/2
Each sub-study has additional and specific inclusion and exclusion criteria.Sub-Studies: Two sub-studies are currently open:GolcAza: evaluates the combination of golcadomide and oral azacitidine in R/R follicular helper T-celllymphoma. PlaTform represents a novel academic initiative dedicated to R/R PTCL, designed toaccelerate therapeutic innovation in this underserved population.Acknowledgement: We wish to thank the patients and their families for their participation in the clinicaltrials, iOnctura for providing access to roginolisib, and Bristol-Myers Squibb for providing access togolcadomide and azacitidine.
- Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD (OCCC - West Halls B3-B4) - Nov 4, 2025 - Abstract #ASH2025ASH_4571;
P3
PlaTform represents a novel academic initiative dedicated to R/R PTCL, designed toaccelerate therapeutic innovation in this underserved population.Acknowledgement: We wish to thank the patients and their families for their participation in the clinicaltrials, iOnctura for providing access to roginolisib, and Bristol-Myers Squibb for providing access togolcadomide and azacitidine. Patients randomized to IC will receive rituximab-lenalidomide (lenalidomide 20mg Days 1
- golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD (OCCC - Tangerine Ballroom F3-4) - Nov 4, 2025 - Abstract #ASH2025ASH_3782;
P1/2
GOLCA+ R induced a decrease in circulating tumor DNA across tumor variants. These data support the ongoingdevelopment of GOLCA + R in patients with R/R non-Hodgkin lymphoma.
- iberdomide (CC-220) / BMS, golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD (OCCC - Tangerine Ballroom F3-4) - Nov 4, 2025 - Abstract #ASH2025ASH_3779;
P1, P3
GOLCA+R-CHOP demonstrated a predictable and manageablesafety profile with low rates of non-hematologic AEs; addition of GOLCA to R-CHOP did not compromiseSOC delivery. These data continue to show that GOLCA 0.4mg, when added to SOC Tx, has a potential tocure more previously untreated pts with HR LBCL and support the ongoing Phase 3 trial, GOLSEEK-1, inthis population (NCT06356129).
- Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Mosunetuzumab (Mosun) or glofitamab (Glofit) in combination with golcadomide (Golca) demonstrates a manageable safety profile and encouraging efficacy in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL) (OCCC - Tangerine Ballroom F2) - Nov 4, 2025 - Abstract #ASH2025ASH_1356;
P1
These data continue to show that GOLCA 0.4mg, when added to SOC Tx, has a potential tocure more previously untreated pts with HR LBCL and support the ongoing Phase 3 trial, GOLSEEK-1, inthis population (NCT06356129). In Arm 2, ptsreceived intravenous obinutuzumab pretreatment on C1D1 and Glofit on C1D8 (2.5mg), D15 (10mg),then D1 of subsequent cycles (30mg); oral Golca was given daily from C2 or C3 onwards (D1
- || Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date: CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 3, 2025
P1, N=121, Recruiting, Sponsor: Hoffmann-La Roche
In Arm 2, ptsreceived intravenous obinutuzumab pretreatment on C1D1 and Glofit on C1D8 (2.5mg), D15 (10mg),then D1 of subsequent cycles (30mg); oral Golca was given daily from C2 or C3 onwards (D1 Trial completion date: Mar 2029 --> Sep 2029 | Trial primary completion date: Mar 2027 --> Sep 2029
- | lenalidomide / Generic mfg., golcadomide (CC-99282) / BMS
Journal: Golcadomide: An Oral CELMoD Agent Targeting IKZF1/3 For Diffuse Large B-Cell Lymphoma. (Pubmed Central) - Nov 3, 2025
Trial completion date: Mar 2029 --> Sep 2029 | Trial primary completion date: Mar 2027 --> Sep 2029 Golcadomide exhibited rapid, deep, and sustained degradation of transcription factors IKZF1 and IKZF3, surpassing the anti-tumor activity of the IMiD
- | golcadomide (CC-99282) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
Enrollment closed: TOP-FLOR: Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD Golcadomide, Rituximab +/- Nivolumab. (clinicaltrials.gov) - Aug 20, 2025
P2, N=40, Active, not recruiting, Sponsor: Olivia Newton-John Cancer Research Institute
Golcadomide exhibited rapid, deep, and sustained degradation of transcription factors IKZF1 and IKZF3, surpassing the anti-tumor activity of the IMiD Recruiting --> Active, not recruiting
- | golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
Enrollment open: FIL_RICCO: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (clinicaltrials.gov) - Aug 18, 2025
P2, N=47, Recruiting, Sponsor: Fondazione Italiana Linfomi - ETS
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | iberdomide (CC-220) / BMS, golcadomide (CC-99282) / BMS, pomalidomide / Generic mfg.
Preclinical, Journal: Novel Cereblon-Binding Immunomodulators Have Increased Potency Against Gammaherpesvirus- Associated Lymphomas In Vitro. (Pubmed Central) - Aug 6, 2025
Next generation CBIs, such as golcadomide (Golc) and iberdomide (Iber), have increased affinity to the primary cellular target, cereblon, making them potentially better anticancer agents...The novel CBIs had relatively little activity in Pom-resistant cell lines with low levels of cereblon, suggesting that binding to cereblon is also important for the functions of the novel CBIs. These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors.
- |||||| golcadomide (CC-99282) / BMS
Enrollment open: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) (clinicaltrials.gov) - Aug 5, 2025
P3, N=400, Recruiting, Sponsor: Celgene
These data show that the newer CBIs are more potent and effective against PEL and BL lines than Pom, and therefore, are worth investigating clinically in patients with these tumors. Not yet recruiting --> Recruiting
- ||| golcadomide (CC-99282) / BMS
Enrollment closed, Trial completion date, Trial primary completion date: CC-99282-NHL-001: A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (clinicaltrials.gov) - Jul 25, 2025
P1/2, N=438, Active, not recruiting, Sponsor: Celgene
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Feb 2028 | Trial primary completion date: Apr 2026 --> Apr 2027
- | Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Phase classification, Adverse events: EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 9, 2025
P2, N=565, Recruiting, Sponsor: Genmab
Recruiting --> Active, not recruiting | Trial completion date: Apr 2027 --> Feb 2028 | Trial primary completion date: Apr 2026 --> Apr 2027 Phase classification: P1/2 --> P2
- || iberdomide (CC-220) / BMS, golcadomide (CC-99282) / BMS
Trial completion date, Trial primary completion date: CC-220-DLBCL-001: Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (clinicaltrials.gov) - Jun 30, 2025
P1, N=174, Recruiting, Sponsor: Celgene
Phase classification: P1/2 --> P2 Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Jun 2027 --> Dec 2028
- || roginolisib (IOA-244) / iOnctura, golcadomide (CC-99282) / BMS
New P1/2 trial: A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas (clinicaltrials.gov) - Jun 12, 2025
P1/2, N=49, Not yet recruiting, Sponsor: The Lymphoma Academic Research Organisation
- | Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Phase classification, Adverse events: EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jun 4, 2025
P1/2, N=565, Recruiting, Sponsor: Genmab
Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Jun 2027 --> Dec 2028 Phase classification: P2 --> P1/2
- | golcadomide (CC-99282) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
Trial completion date, Trial initiation date: Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov) - Jun 4, 2025
P1/2, N=30, Not yet recruiting, Sponsor: Natalie Galanina
Phase classification: P2 --> P1/2 Trial completion date: Jan 2028 --> Apr 2028 | Initiation date: Jan 2025 --> Jun 2025
- |||| golcadomide (CC-99282) / BMS
Trial primary completion date: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) (clinicaltrials.gov) - Jun 2, 2025
P3, N=400, Not yet recruiting, Sponsor: Celgene
Trial completion date: Jan 2028 --> Apr 2028 | Initiation date: Jan 2025 --> Jun 2025 Trial primary completion date: Jul 2030 --> Apr 2028
- golcadomide (CC-99282) / BMS
GOLSEEK-4: A MULTICENTER PHASE 3 RANDOMIZED OPEN-LABEL STUDY COMPARING EFFICACY AND SAFETY OF GOLCADOMIDE + RITUXIMAB VS INVESTIGATOR'S CHOICE IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA () - May 15, 2025 - Abstract #EHA2025EHA_3962;
P3
Commonly used treatment regimens for relapsed/refractory (R/R) FL include non-cross-resistant chemoimmunotherapy or rituximab (R)-lenalidomide (len)...Approximately 400 pts with R/R FL will be randomized 1:1 between GOLCA+R or IC, consisting of R-len or R-chemotherapy (CHOP or bendamustine)... GOLSEEK-4 will evaluate the safety and efficacy of GOLCA+R as a fixed duration, chemotherapy-free, outpatient treatment for R/R FL patients who have received >1 line of systemic therapy.
- HP-001 / Helioson Pharmaceutical
HP-001, AN ORAL IKZF 1/3 MOLECULAR GLUE, DEMONSTRATED SUPERIOR DEGRADATION POTENCY AND SPECIFITY IN THE PRE-CLINICAL MODEL (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3106;
HP-001 is currently in phase 1 clinical trial for a variety of hematologic malignancies. CDE registration number: CTR20242943.
- golcadomide (CC-99282) / BMS
GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_3003;
P1/2
A higher ORR and similar tolerability were observed with GOLCA 0.4mg +R vs GOLCA and GOLCA 0.2mg +R, including in pts with prior len-based and/or T-cell-directed Tx. These data support continued development of GOLCA 0.4mg +R as a fixed-duration, chemo-free, outpatient option in R/R FL, to be evaluated in the Ph3 GOLSEEK-4 study.
- golcadomide (CC-99282) / BMS
GOLCADOMIDE (GOLCA), A CEREBLON E3 LIGASE MODULATOR (CELMOD (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2698;
P1/2
Durable responses were shown in heavily pre-treated patients with R/R DLBCL. Responses were independent of cell of origin and tumor microenvironment status.
- || golcadomide (CC-99282) / BMS
Trial completion date, Trial primary completion date: A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) (clinicaltrials.gov) - May 14, 2025
P1/2, N=85, Recruiting, Sponsor: Bristol-Myers Squibb
Responses were independent of cell of origin and tumor microenvironment status. Trial completion date: Aug 2029 --> Oct 2030 | Trial primary completion date: Dec 2025 --> Jan 2027
- golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
Golcadomide (Auditorium) - May 4, 2025 - Abstract #ICML2025ICML_1093;
- golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
GOLSEEK-1: A Phase 3, Double-Blind, Randomized Study of Golcadomide + R-CHOP vs Placebo + R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma (Cinema Corso) - May 4, 2025 - Abstract #ICML2025ICML_969;
- golcadomide (CC-99282) / BMS
GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT (Exhibition Area) - May 4, 2025 - Abstract #ICML2025ICML_868;
P1/2
Trial completion date: Aug 2029 --> Oct 2030 | Trial primary completion date: Dec 2025 --> Jan 2027 As of 30 Dec 2024, 12 pts received GOLCA in Part A. 22 and 38 received 0.2 and 0.4 mg GOLCA+R in Part B; median (mdn; range) time from initial diagnosis was 59 months (mo) (10
- golcadomide (CC-99282) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS, Rituxan (rituximab) / Roche
Treatment Of newly-diagnosed Follicular Lymphoma with Rituximab, Golcadomide +/- Nivolumab- Interim analysis of the Phase II TOP-FLOR study (Exhibition Area) - May 4, 2025 - Abstract #ICML2025ICML_657;
- golcadomide (CC-99282) / BMS
GOLSEEK-2: A PHASE 2 RANDOMIZED, OPEN-LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED-STAGE FOLLICULAR LYMPHOMA () - May 4, 2025 - Abstract #ICML2025ICML_550;
P2
As of 30 Dec 2024, 12 pts received GOLCA in Part A. 22 and 38 received 0.2 and 0.4 mg GOLCA+R in Part B; median (mdn; range) time from initial diagnosis was 59 months (mo) (10 The phase 1/2 study CC-99282-NHL-001 showed that GOLCA alone or in combination with R (GOLCA+R) was well tolerated, with promising activity in pts with heavily pretreated relapsed/refractory FL, including those with prior lenalidomide-based therapies and/or T-cell
- |||||||||| golcadomide (CC-99282) / BMS
New P3 trial: A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma (GOLSEEK-4) (clinicaltrials.gov) - Apr 7, 2025
P3, N=400, Not yet recruiting, Sponsor: Celgene
- | golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
Enrollment open: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (clinicaltrials.gov) - Apr 4, 2025
P2, N=41, Recruiting, Sponsor: Mayo Clinic
The phase 1/2 study CC-99282-NHL-001 showed that GOLCA alone or in combination with R (GOLCA+R) was well tolerated, with promising activity in pts with heavily pretreated relapsed/refractory FL, including those with prior lenalidomide-based therapies and/or T-cell Not yet recruiting --> Recruiting
- ||| ianalumab (VAY736) / Novartis
Trial termination: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Apr 3, 2025
P1, N=18, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Active, not recruiting --> Terminated; Business decision and not due to any safety or tolerability concerns.
- || iberdomide (CC-220) / BMS, golcadomide (CC-99282) / BMS
Trial completion date, Trial primary completion date: CC-220-DLBCL-001: Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (clinicaltrials.gov) - Mar 24, 2025
P1, N=174, Recruiting, Sponsor: Celgene
Active, not recruiting --> Terminated; Business decision and not due to any safety or tolerability concerns. Trial completion date: Feb 2026 --> Jun 2027 | Trial primary completion date: Dec 2024 --> Jun 2027
- | golcadomide (CC-99282) / BMS
Journal: Leveraging efficiency metrics for the optimization of CELMoDs (Pubmed Central) - Mar 6, 2025
We applied these efficiency metrics retrospectively to track optimization of a clinical molecular glue degrader series, resulting in the identification of Golcadomide (CC-99282). This work illustrates that efficiency metrics are beneficial for the identification of molecular glue drug candidates.
- | golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
New P2 trial: FIL_RICCO: A Combination of Rituximab and CC-99282 as Front-line Therapy for Older Frail Patients With Diffuse Large B-cells Non-Hodgkin Lymphoma Evaluated With a Simplified Geriatric Assessment (sGA): a Phase II Study of the Fondazione Italiana Linfomi (FIL) (clinicaltrials.gov) - Feb 19, 2025
P2, N=47, Not yet recruiting, Sponsor: Fondazione Italiana Linfomi - ETS
- | golcadomide (CC-99282) / BMS, Rituxan (rituximab) / Roche
New P2 trial: Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy (clinicaltrials.gov) - Feb 18, 2025
P2, N=41, Not yet recruiting, Sponsor: Mayo Clinic
- || golcadomide (CC-99282) / BMS, Opdivo (nivolumab) / Ono Pharma, BMS
New P1/2 trial: Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy (clinicaltrials.gov) - Jan 10, 2025
P1/2, N=30, Not yet recruiting, Sponsor: Natalie Galanina
- || Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Trial completion date, Trial primary completion date, Adverse events: EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jan 6, 2025
P2, N=622, Recruiting, Sponsor: Genmab
This work illustrates that efficiency metrics are beneficial for the identification of molecular glue drug candidates. Trial completion date:Jun 2031 --> Nov 2032 | Trial primary completion date: Jun 2031 --> Nov 2032
- || Columvi (glofitamab-gxbm) / Roche, Lunsumio (mosunetuzumab-axgb) / Roche
Trial completion date, Trial primary completion date: CO43805: A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 13, 2024
P1, N=121, Recruiting, Sponsor: Hoffmann-La Roche
Trial completion date:Jun 2031 --> Nov 2032 | Trial primary completion date: Jun 2031 --> Nov 2032 Trial completion date: Jul 2028 --> Mar 2029 | Trial primary completion date: Jul 2026 --> Mar 2027
- golcadomide (CC-99282) / BMS
Carmod, an Open-Label, Multicenter, Proof of Concept, Phase II Trial, Investigating the Safety and Efficacy of Golcadomide in Post-CART for Patients with Relapsed/Refractory High-Risk Aggressive Large B-Cell Lymphoma () - Dec 7, 2024 - Abstract #ASH2024ASH_9255;
P2
Quantitative and qualitative analysis of Minimal Residual Disease by circulating tumor (Ct) DNA will also be assessed.The sponsor of the trial is the Lymphoma Academic Research Organisation (LYSARC) with the support of Bristol Myers Squibb. The first patient has been included on 25 June 2024.
- || Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Trial completion date, Trial primary completion date, Adverse events: EPCORE NHL-5: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Dec 2, 2024
P2, N=622, Recruiting, Sponsor: Genmab
The first patient has been included on 25 June 2024. Trial completion date: Nov 2032 --> Jun 2031 | Trial primary completion date: Nov 2032 --> Jun 2031
- | ianalumab (VAY736) / Novartis
Trial completion date, Trial primary completion date: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 29, 2024
P1, N=18, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Nov 2032 --> Jun 2031 | Trial primary completion date: Nov 2032 --> Jun 2031 Trial completion date: Oct 2026 --> Feb 2025 | Trial primary completion date: Oct 2026 --> Feb 2025
- golcadomide (CC-99282) / BMS
Golseek-2: A Phase 2 Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Golcadomide in Combination with Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lymphoma (Halls G-H (San Diego Convention Center)) - Nov 21, 2024 - Abstract #ASH2024ASH_7223;
P2
Trial completion date: Oct 2026 --> Feb 2025 | Trial primary completion date: Oct 2026 --> Feb 2025 R-lenalidomide (R-Len), a chemo-free alternative to R-based chemoimmunotherapy, has recently been listed as a chemo-free option in the National Comprehensive Cancer Network
- golcadomide (CC-99282) / BMS
Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3) (Halls G-H (San Diego Convention Center)) - Nov 21, 2024 - Abstract #ASH2024ASH_7197;
P1/2
ORR in the ATL cohort is evaluated by assessment per international consensus response criteria for ATL with slight modifications; ORR in the PTCL cohort is evaluated by assessment per response criteria according to Lugano Classification (CT-based). Status The trial is ongoing, and patients will be recruited from 40 sites in Japan.
- golcadomide (CC-99282) / BMS
Golseek-1: A Phase 3, Double-Blind, Randomized Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Vs R-CHOP in Patients with Previously Untreated, High-Risk, Large B-Cell Lymphoma (Halls G-H (San Diego Convention Center)) - Nov 21, 2024 - Abstract #ASH2024ASH_7165;
P3
Status The trial is ongoing, and patients will be recruited from 40 sites in Japan. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), typically administered for 6 cycles, is the standard therapy for DLBCL and is curative in ~60